ClinicalTrials.gg
CompletedNCT00110799Updated Jun 4, 2012

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

A Phase 2 interventional study of SB497115 and Placebo in Hepatitis C, Chronic, Hepatitis C and Thrombocytopenia, sponsored by GlaxoSmithKline. Completed at 30 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-04.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hepatitis C, Chronic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · GlaxoSmithKline.

Enrollment
7th of 14
75 · median 62
Started
2005
with 2 others
Phase 2
6 of 14
none open now
Registered
1st of 14
by date

Among the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline, this one is the 7th largest by enrollment, is one of 3 that started in 2005, is one of 6 in phase 2, and was the 1st registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline as a file.
02

Study summary

SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 as a treatment for patients with chronic hepatitis C-related thrombocytopenia who are potential candidates for antiviral treatment with pegylated interferon and ribavirin. The study will be conducted in two phases, Parts 1 and 2. In Part 1, study subjects will be randomized to 4 weeks of SB-497115-GR or placebo administered daily without antiviral therapy. Subjects who successfully complete Part 1 (platelet count 70,000/µL for Pegasys and platelet count 100,000/µL for PEG-Intron) will then proceed to Part 2. In Part 2, subjects will receive an additional 8 weeks of SB-497115-GR or placebo administered daily with antiviral therapy.

Read the detailed description

A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre, Dose-Ranging, Parallel Group, Phase II Study to Assess Efficacy, Safety/Tolerability, and Pharmacokinetics of a Thrombopoietin Receptor Agonist, SB-497115-GR, when Administered as 30, 50, and 75 mg Once Daily for 12 weeks in Subjects with Chronic Hepatitis C-Related Thrombocytopenia who are Potential Candidates for Antiviral Treatment with Pegylated Interferon and Ribavirin.

03

Conditions studied

  • Hepatitis C, Chronic
  • Hepatitis C
  • Thrombocytopenia

Keywords

  • thrombopoietin
  • platelets
  • Hepatitis C-related thrombocytopenia
  • Hepatitis C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic low count between 20,000 and \<70,000/µL.
  • Prior liver indicating chronic hepatitis within the previous 5 years or radiographic evidence of cirrhosis and / or endoscopic evidence of non-bleeding esophageal or gastric varices.

Exclusion criteria

Exclusion criteria:

  • History of heart attack or abnormal heart function.
  • History of thrombosis within 1 year.
  • History of alcohol or drug abuse or dependence within 1 year.
  • Use of aspirin, aspirin-containing compounds, salicylates, antacids.
  • History of infection or active infection with or C.
  • Females who are pregnant.
  • Patients using non-steroidal anti-inflammatory drugs during the study and within 3 weeks prior to starting the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Active comparator
    Arm B

    SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

    Drug: SB497115

  • Active comparator
    Arm C

    SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

    Drug: SB497115

  • Active comparator
    Arm D

    SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

    Drug: SB497115

  • Placebo comparator
    Arm A

    Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

    Other: Placebo

Interventions

  • Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

  • OtherPlacebo

    Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

06

What researchers measure

Primary outcomes

  1. Treatment response, assessed by the proportion of subjects with a shift from baseline platelet count (20, 000 to <70,000µL) to =100,000/µL after 4 weeks of study treatment.

    Time frame: 4 weeks

Secondary outcomes

  1. Mean increase in platelet counts and markers of thrombopoiesis. Safety and tolerability, population PK, pharmacodynamics. Effect of antiviral outcome measures during and after therapy.

    Time frame: 4 weeks

07

Study locations

30 sites
  • GSK Investigational Site
    Denver, Colorado 80262, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    St. Louis, Missouri 63104, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
  • GSK Investigational Site
    Fairfax, Virginia 22031, United States
  • GSK Investigational Site
    Richmond, Virginia 23249, United States
  • GSK Investigational Site
    Clermont Ferrand Cédex 1, 63058, France
  • GSK Investigational Site
    Clichy Cedex, 92118, France
  • GSK Investigational Site
    Lyon Cedex 02, 69288, France
  • GSK Investigational Site
    Lyon, 69437, France
  • GSK Investigational Site
    Marseille Cedex 08, 13285, France
  • GSK Investigational Site
    Nice Cedex 03, 06202, France
  • GSK Investigational Site
    Paris Cedex 12, 75571, France
  • GSK Investigational Site
    Pessac Cedex, 33604, France
  • GSK Investigational Site
    Vandoeuvre Les Nancy, 54511, France
  • GSK Investigational Site
    Heidelberg, Baden-Wuerttemberg 69120, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60590, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Homburg, Saarland 66421, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    San Juan, 00909-1711, Puerto Rico
  • GSK Investigational Site
    Bristol, Gloucestershire BS2 8HW, United Kingdom
  • GSK Investigational Site
    Glasgow, Lanarkshire G12 0YN, United Kingdom
  • GSK Investigational Site
    Nottingham, Nottinghamshire NG7 2UH, United Kingdom
  • GSK Investigational Site
    London, NW3 2QG, United Kingdom
  • GSK Investigational Site
    London, W2 1NY, United Kingdom
08

References and documents

Publications

  • McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH; TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36. doi: 10.1056/NEJMoa073255. PubMed 18046027 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Oct 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2005
First posted
May 16, 2005
Start
Apr 2005
Primary completionActual
Oct 2006
CompletionActual
Nov 2006
Last update
Jun 4, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00110799
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 16, 2005
Start date
Apr 2005
Primary completion
Oct 2006
Completion
Nov 2006
Last update
Jun 4, 2012

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion